metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-25 SLOWER FIBROSIS PROGRESSION IN HEPATITIS C HEMOPHILIAC PATIENTS?
Información de la revista
Vol. 24. Núm. S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(septiembre 2021)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 24. Núm. S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(septiembre 2021)
Open Access
P-25 SLOWER FIBROSIS PROGRESSION IN HEPATITIS C HEMOPHILIAC PATIENTS?
Visitas
452
Dauana O. Bastos, Christini Emori, Sandra V. Antunes, Flavia Appel, Maria Lucia Ferraz
Universidade Federal de São Paulo, São Paulo, Brazil
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 24. Núm S1

Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)

Más datos
Introduction

The improvement in the treatment of hemophilia from the 90′s, as well as the advent of interferon-free therapy against HCV enabled a better evolution of these special group of patients. However, the impact of hemophilia on the progression of liver fibrosis is still not completely understood.

Objectives

To evaluate the progression of liver fibrosis in hemophiliac patients with HCV using non-invasive methods after ten years of follow-up.

Casuistic and Method

Retrospective cohort study of hemophiliac patients with HCV evaluated in 2007 and reassessed 10 years later (2017/2018). Hepatic fibrosis was indirectly evaluated by APRI and transient hepatic elastography by Fibroscan ® - EHT).

Results

Sixty-six hemophiliac patients were evaluated in 2007 (all men, median age 31.5 years, 87.9% hemophilia A). Forty-two patients could be reevaluated in 2017/2018. Thirty-three patients were treated with 90.9% SVR; thus, after 10 years, 30 patients were non-viremic and 12 were viremic (3 without SVR and 9 untreated). APRI values were low in both periods but showed a significant reduction in treated patients (0.36 vs 0.20, p <0.001), remaining stable in non-treated (0,61 vs 0,51, p=NS). Fibrosis by EHT was assessed only in 2017/2018 and also showed results compatible with low stages of fibrosis in treated and even in non-treated patients (4.75 and 5.25 kPa, respectively).

Conclusions

After ten years of follow-up the results suggest a slower progression and a more benign evolution of hepatic fibrosis among hemophiliacs. Antiviral therapy against HCV showed an elevated response rate, similar to the general population.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos